Invion Limited Overview
Invion Limited is a Melbourne-based, micro-capitalisation clinical-stage life-sciences company developing Photosoft™, a next-generation photodynamic therapy (NGPDT) platform comprising a library of more than 300 photosensitiser compounds. Its lead candidate, INV043, is a light-activated photosensitiser being studied in topical, sublingual and intravenous forms across non-melanoma skin cancer, anogenital cancers, prostate and oesophageal cancer, with theranostic potential (therapeutic activation under 660nm red light and diagnostic fluorescence under 405nm violet light). In December 2025 Invion converted a patchwork of territory-limited licences from the technology's inventor group (RMW Cho Group) into a perpetual, exclusive global licence for a portfolio of "Agreed Indications" across human and animal health, paid in milestone-linked shares and royalties. The company operates a capital-light, partner-funded model — Hanlim Pharm (oesophageal, supported by a Korean government grant), SANGMYUNG Innovation (wet AMD) and Protect Animal Health (companion animal oncology) — but faces acute funding constraints, with A$0.59M cash at 30 June 2026 and a going-concern emphasis from its auditor.
Company's own description (paraphrased from FY2026 Annual Report)
In its FY2026 Directors' Report, Invion describes itself as a clinical-stage life-science company leading the global research and development of Photosoft™ technology for treating a range of cancers and infectious diseases in both human and animal health. It holds an expanded, perpetual and exclusive global licence to Photosoft™ carrying rights to develop, manufacture, market, distribute, sub-license and otherwise commercialise the technology for a defined portfolio of "Agreed Indications". The company states it partners with research institutes, notably the Peter MacCallum Cancer Centre (Peter Mac) and the Hudson Institute of Medical Research, to develop a novel photosensitiser intended to improve treatment of skin cancers and hard-to-treat solid tumours, with the aim of more effective targeting and killing of cancer cells with fewer side effects and minimal discomfort.
Independent characterisation
| Period | Model | Revenue source |
|---|---|---|
| FY2018–FY2024 | Contract R&D service provider to the technology owner: RMWCG funded Photosoft™ cancer R&D in Australia/NZ under a 31 Aug 2017 R&D Services Agreement, with revenue recognised on a fully-burdened cost basis | R&D services fees from RMWCG (A$3.29M FY2022; A$4.10M FY2023; A$3.69M FY2024) |
| FY2025 | Transitional; RMWCG stopped settling invoices; ~A$4.07M receivable fully provided | Nil revenue |
| FY2026 onward | Global licensee and platform out-licensor; partner-funded preclinical work; future royalties/sub-licensing | Non-clinical research funding from Hanlim Pharm (A$384,707 in FY2026) |
Invion is, in substance, a virtual biotech and IP-licensing vehicle. It owns no laboratories or manufacturing plants; R&D is executed through contract research organisations, clinical sites (Veracity Clinical Research and Cornerstone Dermatology in Queensland), academic partners (Peter Mac, Hudson Institute, University of Adelaide's ACARE) and outsourced chemistry/manufacturing providers. Its core asset is a licence (carried at A$7.46M on the balance sheet at 30 June 2026) to a photosensitiser library invented by Michael Honsue Cho, controller of RMW Cho Group Limited (RMWCG) and the newly formed licensor entity NGPDT IP (Holdings) Pty Ltd.
Business model evolution:
Revenue model mix (FY2026): 100% contract research/service funding from one customer (Hanlim Pharm Co., Ltd, South Korea). Product revenue: nil. Licensing/royalty income: nil to date. Subscription: not applicable.
Value chain position: Upstream drug discovery and early clinical development (preclinical to Phase I/II). Invion's strategy contemplates sub-licensing to pharmaceutical partners for late-stage development and commercialisation; under the prior territory licences a 50% sub-licence fee share was payable to RMWCG, while the new global licence provides for royalties on future net sales and certain sub-licensing or analogous payments (exact rates not publicly disclosed in the sources reviewed).
Customer types: (i) pharmaceutical and biotech partners (Hanlim Pharm, SANGMYUNG Innovation, Dr. I&B Co., Ltd., Protect Animal Health Inc.); (ii) historically, the technology licensor (RMWCG) as R&D services customer. Ultimately, end-users would be dermatologists, oncologists, ophthalmologists and veterinarians.
End-markets targeted: Non-melanoma skin cancer (SCC, BCC); anogenital cancers (anal, vulvar, penile); oesophageal cancer; prostate cancer; glioblastoma multiforme; HPV-related disease; wet age-related macular degeneration; companion-animal oncology; infectious diseases (antimicrobial-resistant bacteria, fungi, viruses); atherosclerosis; periodontal disease.
Strategy
Stated strategy themes (paraphrased from FY2025/FY2026 Annual Reports and announcements)
-
Platform breadth via global licensing: Use the perpetual global licence for "Agreed Indications" — selected for attractive addressable markets and/or unmet need, with an eye to US FDA Orphan Drug Designation opportunities — as the basis for partnering and commercialisation.
-
Disciplined, partner-funded development: Keep Invion's own spend focused on the relatively low-cost NMSC trial while other preclinical and clinical studies are subsidised or fully funded by partners, minimising dilution.
-
Retain all IP: Every collaboration (Hanlim, SANGMYUNG, Protect, Dr. I&B) is structured so that Invion retains rights to Photosoft™ and any new IP arising.
-
Clinical credibility: Strengthen clinical leadership (Hopper, Ramsay) and leverage leading institutions (Peter Mac, Hudson).
-
Expand addressable markets: Move beyond human oncology into ophthalmology (wet AMD) and animal health (companion-animal cancer).
-
Commercial transactions: Management's stated likely developments include expanding commercial partnerships with global healthcare companies and securing one or more commercial transactions for its drug assets.
Strategic initiatives — last 24 months (Oct 2024 – Oct 2026)
| Date | Initiative | Type | Financial terms / targets |
|---|---|---|---|
| 16 Oct 2024 | 100:1 share consolidation | Capital structure | Reduce share count from ~6.8B to ~68M |
| FY2025 | Phase I/II NMSC trial launched (Queensland) | Clinical | Invion-funded |
| FY2025 | Hanlim collaboration expanded to oesophageal cancer (plus GBM) | Partnership | Hanlim-funded preclinical |
| 5 Jun 2025 | Formation of Photo Geni, Photo Derm, Photo Lung subsidiaries | Corporate | Dormant vehicles |
| Jul 2025 | Loyalty options entitlement offer (underwritten by Blue Ocean Equities) | Funding | A$980,339 raised; 65.35M options at A$0.015, exercise A$0.14 |
| Aug 2025 | FDA Orphan Drug Designation — INV043 in anal cancer | Regulatory | 7-year US exclusivity post-approval; tax credits; fee waivers |
| Oct 2025 | Exit from Lind Partners facility | Funding / cost | A$1,145,990 repaid; no further obligations |
| 21 Oct 2025 | Protect Animal Health collaboration | New market | Protect funds evaluation studies |
| 18 Nov 2025 | Pharmbridge Pty Ltd formed | Corporate | Hanlim contracting vehicle |
| Dec 2025 | Expanded perpetual exclusive global licence | Transformational IP | Up to 36,705,966 shares in three clinical-milestone tranches + royalties; release of ~A$4.07M receivable claim |
| 23 Dec 2025 | Hanlim / KDDF oesophageal cancer funding | Non-dilutive funding | Up to A$2M |
| 30 Jan 2026 | Convertible note raise anchored by Chair and a major shareholder | Funding | ~A$1.25M (A$1M committed by Chew and another major shareholder) |
| Feb 2026 | R&D tax-incentive financing | Funding | A$400k at 16% p.a. |
| 19 May 2026 | SANGMYUNG wet AMD collaboration | New market | SANGMYUNG funds PoC studies |
| Q4 FY2026 | Clinical Advisor appointment (Dr Colin Hopper) | Capability | — |
| 18 Aug 2026 | Board refresh: Paul Field (BD/licensing expertise) | Governance | — |
ESG/sustainability commitments: None disclosed. Cost programs: No formal program with targets; management states it has "significant flexibility to delay or scale down R&D" to align with cash, and directors are deferring cash remuneration.
Medium-term financial targets / guidance
Not publicly disclosed. Invion provides no revenue, earnings or cash-burn guidance. It expects RDTI refunds (~A$539,520 claimed for FY2025, under ATO assessment) and states flexibility to finance against the FY2026 RDTI claim.
Products & Services
Invion has no marketed products. All entries below are development-stage programs within the single Photosoft™ segment. Pricing models are not publicly disclosed for any program.
Platform
Photosoft™ (Next Generation Photodynamic Therapy, NGPDT)
Description: A library of more than 300 unique photosensitiser compounds (SANGMYUNG announcement, 19 May 2026; FY2026 Annual Report). PDT uses a non-toxic photosensitiser that, when activated by light of a specific wavelength, generates reactive oxygen species that kill target cells and may stimulate anti-tumour immune responses.
Claimed differentiation: Improved tumour targeting; reduced pain versus existing PDT (clinicians reported no signs of pain in the NMSC trial); theranostic capability (treatment and diagnosis with one agent).
IP: Australian Patent No. 2021388872 extends protection to at least late 2041; earlier patents expire around 2033 (FY2023 Annual Report). IP legal ownership is being transferred from RMWCG to NGPDT IP (Holdings) Pty Ltd within 12 months of the December 2025 deal.
Licence status: Perpetual, exclusive, global for "Agreed Indications" (human and animal).
Lead drug candidate — INV043 (also designated HL270 in the Hanlim program)
| Formulation / Program | Indication | Stage (latest) | Key data / specifications | Partner / funder | Latest milestone year |
|---|---|---|---|---|---|
| Topical INV043 ointment | Non-melanoma skin cancer — squamous cell carcinoma (SCC) | Phase I/II adaptive platform protocol, Queensland | First six patients: no INV043-related adverse events; no pain reported; lesion-size reduction at 15 and 30 days after one cycle vs slight growth in untreated matched lesions; Part 2 adjusting drug-light interval; FY2026: tumour necrosis and lesion reduction (p<.05), complete resolution in select cases (durability under evaluation) | Invion-funded (relatively low cost) | FY2025–FY2026 |
| Topical INV043 ointment | NMSC — basal cell carcinoma (BCC) cohort | Newly authorised cohort after SRC approval | BCC ≈80% of skin cancer incidence (company statement) | Invion | FY2026 |
| Topical INV043 + PD-1 inhibitor | Anogenital cancers (anal, vulvar, penile) | Trial in preparation at Peter Mac (ethics submission in preparation) | Preclinical (mice): ~80% complete pathological response with INV043 + PD-1 vs 12.5% with PD-1 alone; US FDA Orphan Drug Designation (anal cancer), Aug 2025; A$20k CSSANZ Foundation grant to Prof Sandy Heriot | Peter Mac | FY2025–FY2026 |
| Sublingual INV043 | Prostate cancer | Investigator-led Phase II completed (sponsored by RMWCG) | Six cycles, monotherapy; no serious adverse events; 40% positive response, 10% complete regression (RECIST 1.1); 44% PSMA-PET negative at 3 months; clinical study summary compiled by Scendea Limited | RMWCG | Results Sep 2024 |
| Intravenous INV043 (HL270) | Oesophageal cancer | Preclinical / IND-enabling; planned Australian first-in-human trial | Up to A$2M funding; A$394,970 received to 30 Jun 2026 | Hanlim Pharm (KDDF grant) | Dec 2025 |
| INV043 (route not disclosed) | Glioblastoma multiforme | Preclinical | Partner-funded studies; Invion retains IP | Hanlim Pharm | FY2024–FY2025 |
| INV043 / diagnostic use | Surgical margin delineation (theranostic) | Exploratory in NMSC trial | 405nm violet light induces cancer-cell fluorescence; 660nm red light activates cytotoxicity | Invion | FY2025 |
Other Photosoft™ compounds and programs
| Program | Indication | Stage | Partner | Notes |
|---|---|---|---|---|
| Ophthalmology | Wet AMD and other retinal vascular diseases | Proof-of-concept preclinical efficacy studies | SANGMYUNG Innovation Co., Ltd. (funds and conducts) | First ophthalmology deal (19 May 2026); combines Photosoft with SANGMYUNG's ocular delivery technology |
| Companion animal oncology | Cancer in pets | In vitro, in vivo and companion-animal evaluation studies | Protect Animal Health Inc. (TWSE/TPEx: 7850; funds and conducts) | Signed Oct 2025; may lead to co-development agreement |
| HPV | HPV-related disease | Preclinical | Dr. I&B Co., Ltd. | Initiated FY2024 |
| Infectious diseases | MRSA, E. coli, Candida albicans | In vitro | ACARE, University of Adelaide | FY2023 data |
| Antiviral | Zika, Dengue, SARS-CoV-2 (Delta, Omicron BA.1) | In vitro | Independent labs | Nine of ten compounds showed activity vs SARS-CoV-2 variants (FY2023 Annual Report) |
| Periodontal disease | Gum disease | Early exploratory | — | Focus initiated FY2024 |
| Solid tumours (breast, lung, ovarian) | Including triple-negative breast cancer | Preclinical | Hudson Institute | PoC data supported INV043 selection |
| Atherosclerosis | Cardiovascular | Licensed indication (prior APAC rights); no active program disclosed | — | Prior option for US/Canada/HK atherosclerosis rights at A$1M (superseded) |
Legacy / divested assets
| Asset | Status |
|---|---|
| INV102 (nadolol) — asthma, smoking cessation, COPD | Demerged to Chronic Airway Therapeutics (2018) |
| INV104 (zafirlukast) | Demerged to Chronic Airway Therapeutics (2018) |
| Cpn10 (CBio heritage) — lupus/autoimmune | Discontinued; no further disclosure |
Financial Narrative
Income statement
Sources: FY2023 Annual Report (FY2022–FY2023), FY2025 Annual Report (FY2024–FY2025), FY2026 Annual Report (FY2026). EBITDA and adjusted EPS computed (FY2022/FY2023 EPS restated for the 100:1 consolidation of 16 Oct 2024 using weighted shares of 6,117.4M and 6,419.6M ÷ 100). Finance costs relating to the Lind facility were classified within administrative expenses in FY2024 (A$240,000) and FY2025 (A$694,775); FY2026 administrative expenses include A$993,060 "Lind administrative cost" plus separately reported finance costs of A$346,796 and a derivative fair-value gain of A$376,924.
Margins and growth
Gross profit/gross margin: Invion does not report cost of sales; its service revenue was recognised on a cost-plus/fully-burdened basis, so a gross margin is not meaningful (aggregators such as Simply Wall St display gross profit equal to revenue). Revenue CAGR FY2022–FY2026: −41.5% (computed), though this is distorted by the change of revenue counterparty and should not be read as an operating trend.
Commentary. The P&L divides into two eras. Through FY2024, Invion was effectively a cost-reimbursed contractor to RMWCG: revenue of A$3.3–4.1M offset most R&D spend, and statutory losses were modest (A$1.6–2.2M) apart from FY2024. The inflection came in FY2024, when RMWCG stopped paying; Invion recognised a ~A$3.7M impairment through the P&L (notes cite a A$4.07M expected-credit-loss allowance — see discrepancy note below), turning a ~A$1.9M underlying loss into A$5.6M. FY2025 had no revenue and was further burdened by a sharp acceleration of licence amortisation (A$4.8M) after management cut the licences' assessed useful life from 20 years to 10 years — a non-cash but material signal about expected economic life. FY2026's loss narrowed to A$5.6M as amortisation normalised (A$1.7M) and Hanlim-funded revenue resumed, but cash-relevant overheads rose: administrative expenses of A$2.1M exceed R&D (A$1.5M), inflated by Lind facility costs (A$1.0M) — an unfavourable mix for a development company.
Half-year snapshot (H1 FY2026, six months to 31 Dec 2025)
Source: Appendix 4D lodged 27 Feb 2026 (via InvestSMART summary). The review report carried an emphasis on going concern.
Balance sheet
Sources: Annual Reports. Net debt and working capital computed. FY2026 "borrowings" comprise R&D financing A$425,956 (A$400,000 principal at 16% p.a. plus accrued interest), convertible-note host liability A$1,100,967 and derivative liability A$20,638. Convertible notes mature 5 Mar 2029 but are classified as current (conversion feature).
Commentary. The balance sheet has been eroded from A$19.6M equity (FY2022) to A$5.3M (FY2026), with intangibles now 91% of total assets and net tangible assets negative (−1.96 cents per share at 30 Jun 2026). Cash fell from A$8.5M after the FY2022 raisings to A$0.59M; working capital swung negative in FY2025. Management notes that A$408,742 of current liabilities are unpaid salaries and director fees owed to current directors, and A$1.12M relates to convertible notes requiring no cash settlement — excluding those, the adjusted net current liability position is ~A$0.62M (FY2026 Annual Report, going-concern note). Accumulated losses of A$148.8M against A$152.6M of contributed capital show that nearly all capital raised over 25 years (much of it under the CBio/Inverseon strategy) has been consumed.
Cash flow
Sources: Annual Reports; FCF computed. FY2025 "debt proceeds" = receipts from Lind Partners; FY2026 = net borrowings A$1,985,827 (convertible notes) plus R&D financing A$400,000. FY2026 operating receipts from customers were A$384,413 (Hanlim).
Commentary. Underlying operating burn has been steady at A$2.4–3.0M per year since FY2024 — modest in absolute terms but large relative to a A$4M market capitalisation and A$0.59M cash. Between FY2022 and FY2024, Invion spent A$10.65M of shareholders' cash on territory licence payments to RMWCG (a related-party associate) — more than three years of operating burn. Those payments were capitalised, then amortised at an accelerated rate, and ultimately superseded by the December 2025 global licence. FY2026 financing relied on listed loyalty options (A$0.98M), convertible notes (A$2.03M gross across Oct 2025 and Mar/Jun 2026) and R&D tax-incentive pre-funding (A$0.4M), with A$1.15M used to exit the Lind facility.
Ratios
All computed from Annual Report data. Net debt/EBITDA and interest coverage are not meaningful (negative EBITDA; FY2026 finance costs A$346,796 against operating loss of A$5.66M). Cash conversion cycle not meaningful (no inventory; receivables fully impaired; service revenue).
Trend summary. Every return metric deteriorated from FY2023 to FY2025 and remained deeply negative in FY2026. Liquidity ratios show the clearest stress: the current ratio fell from 18.7x to 0.24x in four years. The company's first financial debt appeared in FY2026, albeit structured as equity-convertible.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Ownership | Incorporated | Function (as disclosed or inferred) |
|---|---|---|---|
Invion Limited | Parent (listed) | 2000 | Holds Photosoft™ licence; contracts R&D |
EpiTech Dermal Science Pty Ltd (formerly IVX Cosmetics Pty Ltd) | 100% | Pre-FY2022 | Dermal/cosmetic application vehicle; no disclosed operations |
Photo Geni Pty Ltd | 100% | 5 Jun 2025 | Dormant at 30 Jun 2025; name suggests anogenital indication vehicle (inference) |
Photo Derm Pty Ltd | 100% | 5 Jun 2025 | Dormant; name suggests dermatology vehicle (inference) |
Photo Lung Pty Ltd | 100% | 5 Jun 2025 | Dormant; name suggests lung cancer vehicle (inference) |
Pharmbridge Pty Ltd | 100% | 18 Nov 2025 | Contracting party for the Hanlim oesophageal cancer research funding agreement |
Results by Segment and Segment Margins & Growth (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Segment revenue — Photosoft drug development (AUD K) | 3,292 | 4,105 | 3,694 | 0 | 385 |
Segment operating profit/loss (AUD K) | -2,241 | -1,615 | -5,628 | -8,808 | -5,663 |
Segment pre-tax profit/loss (AUD K) | -2,241 | -1,615 | -5,628 | -8,808 | -5,633 |
Segment operating margin (%) | -68.1 | -39.3 | -152.3 | — | -1,472.1 |
Revenue YoY growth (%) | — | 24.7 | -10.0 | -100.0 | — |
Contribution to group revenue (%) | 100 | 100 | 100 | — | 100 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (AUD K) | 3,292 | 4,105 | 3,694 | 0 | 385 |
Other income incl. interest (AUD K) | 80 | 34 | 49 | 3 | 1 |
Employee benefits expense (AUD K) | 748 | 710 | 588 | 592 | 527 |
Research and development expense (AUD K) | 2,323 | 2,898 | 2,691 | 1,290 | 1,483 |
Administrative and corporate expense (AUD K) | 1,161 | 1,091 | 1,346 | 2,019 | 2,118 |
Share-based payment expense (AUD K) | 959 | 371 | 234 | 94 | 199 |
Depreciation and amortisation (AUD K) | 422 | 683 | 816 | 4,815 | 1,722 |
Impairment of receivables (AUD K) | 0 | 0 | 3,697 | 0 | 0 |
Operating profit/loss (AUD K) | -2,241 | -1,615 | -5,628 | -8,808 | -5,663 |
EBITDA (AUD K) | -1,819 | -932 | -4,812 | -3,993 | -3,941 |
Net finance items incl. derivative fair value gain (AUD K) | 0 | 0 | 0 | 0 | 30 |
Pre-tax profit/loss (AUD K) | -2,241 | -1,615 | -5,628 | -8,808 | -5,633 |
Income tax (AUD K) | 0 | 0 | 0 | 0 | 0 |
Net profit/loss (AUD K) | -2,241 | -1,615 | -5,628 | -8,808 | -5,633 |
Basic EPS as reported (AUD cents) | -0.04 | -0.03 | -8.76 | -12.22 | -6.26 |
Basic EPS consolidation-adjusted (AUD cents) | -3.66 | -2.52 | -8.76 | -12.22 | -6.26 |
Diluted EPS (AUD cents, consolidation-adjusted) | -3.66 | -2.52 | -8.76 | -12.22 | -6.26 |
Dividends per share (AUD cents) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating margin (%) | -68.1 | -39.3 | -152.3 | — | -1,472.1 |
EBITDA margin (%) | -55.3 | -22.7 | -130.3 | — | -1,024.4 |
Net margin (%) | -68.1 | -39.3 | -152.3 | — | -1,464.2 |
Revenue YoY growth (%) | — | 24.7 | -10.0 | -100.0 | — |
Balance Sheet (AUD)
| Item | H1 FY2026 | H1 FY2025 |
|---|---|---|
Loss after tax (AUD) | 3,565,836 | 1,872,230 |
Total assets at period end (AUD) | 8,088,461 | — |
Net assets at period end (AUD) | 5,706,180 | — |
Balance Sheet and Share Count (millions)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (AUD K) | 20,041 | 19,047 | 15,451 | 9,489 | 8,167 |
Cash and cash equivalents (AUD K) | 8,473 | 4,085 | 784 | 850 | 592 |
Total current assets (AUD K) | 8,648 | 5,761 | 2,081 | 933 | 697 |
Intangibles — Photosoft licences (AUD K) | 11,393 | 13,228 | 13,331 | 8,535 | 7,464 |
Goodwill (AUD K) | 0 | 0 | 0 | 0 | 0 |
Total current liabilities (AUD K) | 462 | 651 | 1,014 | 1,238 | 2,847 |
Short-term debt (AUD K) | 0 | 0 | 0 | 0 | 1,548 |
Long-term debt (AUD K) | 0 | 0 | 0 | 0 | 0 |
Total debt (AUD K) | 0 | 0 | 0 | 0 | 1,548 |
Net debt (AUD K) | -8,473 | -4,085 | -784 | -850 | 955 |
Total equity (AUD K) | 19,579 | 18,396 | 14,438 | 8,251 | 5,320 |
Working capital (AUD K) | 8,185 | 5,110 | 1,067 | -305 | -2,149 |
Issued capital (AUD K) | 146,544 | 146,883 | 148,355 | 151,207 | 152,596 |
Accumulated losses (AUD K) | -130,836 | -130,475 | -136,080 | -144,541 | -148,806 |
Shares on issue, consolidation-adjusted (millions) | 64.17 | 64.22 | 66.05 | 84.88 | 109.20 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (AUD K) | -1,109 | -1,813 | -2,401 | -2,969 | -2,374 |
Payments for licences / intangibles (AUD K) | -7,250 | -2,500 | -900 | 0 | -65 |
Payments for property, plant and equipment (AUD K) | 0 | -76 | 0 | 0 | -4 |
Free cash flow after all capex (AUD K) | -8,359 | -4,389 | -3,301 | -2,969 | -2,442 |
Free cash flow excluding licence payments (AUD K) | -1,109 | -1,889 | -2,401 | -2,969 | -2,378 |
Net financing cash flow (AUD K) | 15,796 | 0 | 0 | 3,036 | 2,184 |
Gross equity proceeds incl. listed options (AUD K) | 16,638 | 0 | 0 | 2,500 | 980 |
Debt and quasi-debt proceeds (AUD K) | 0 | 0 | 0 | 1,450 | 2,386 |
Debt repayments (AUD K) | 0 | 0 | 0 | -744 | -1,146 |
Dividends paid (AUD K) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD K) | 0 | 0 | 0 | 0 | 0 |
Net change in cash (AUD K) | 7,437 | -4,389 | -3,301 | 67 | -258 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Return on equity, year-end equity (%) | -11.4 | -8.8 | -39.0 | -106.7 | -105.9 |
Return on assets, year-end assets (%) | -11.2 | -8.5 | -36.4 | -92.8 | -69.0 |
ROIC, operating loss / (equity + debt − cash) (%) | -20.2 | -11.3 | -41.2 | -119.0 | -90.2 |
Current ratio (x) | 18.70 | 8.85 | 2.05 | 0.75 | 0.24 |
Debt to equity (x) | 0 | 0 | 0 | 0 | 0.29 |
Asset turnover (x) | 0.16 | 0.22 | 0.24 | 0.00 | 0.05 |
R&D expense / revenue (%) | 70.6 | 70.6 | 72.8 | — | 385.4 |
Revenue by Region
| Region | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Hong Kong — RMW Cho Group, R&D services (AUD K) | 3,292 | 4,105 | 3,694 | 0 | 0 |
South Korea — Hanlim Pharm, non-clinical research (AUD K) | 0 | 0 | 0 | 0 | 385 |
Australia (AUD K) | 0 | 0 | 0 | 0 | 0 |
Total revenue (AUD K) | 3,292 | 4,105 | 3,694 | 0 | 385 |
Growth by region (%)
| Growth by region (%) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Hong Kong YoY (%) | 24.7 | -10.0 | -100.0 | n/m |
South Korea YoY (%) | — | — | — | new |
Share Price and Market Valuation
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Share price at 30 June (AUD) | 0.90 | 0.40 | 0.40 | 0.11 | 0.04 |
Market capitalisation at 30 June (AUD Mn) | 57.7 | 25.7 | 26.4 | 9.3 | 4.4 |
Shares on issue at 30 June (millions) | 64.17 | 64.22 | 66.05 | 84.88 | 109.20 |
Change by Horizon
| Horizon | Change | Basis |
|---|---|---|
Calendar YTD to 24 Sep 2026 | −59.1% | MarketScreener |
1-year (to Aug 2026) | −58.3% | Investing.com |
3-year (30 Jun 2023 A$0.40 → ~A$0.038) | ≈ −90% | Computed |
5-year (30 Jun 2021 A$1.30 → ~A$0.038) | ≈ −97% | Computed |
52-week range | A$0.032 – A$0.20 | Investing.com |
Valuation Multiples
| Multiple | Invion | Peer note |
|---|---|---|
Market cap | ~A$4.2M | — |
Enterprise value | ~A$5.1–5.2M (computed: market cap + A$1.55M debt − A$0.59M cash; MarketScreener A$5.21M) | — |
P/E | Negative (n/m); MarketScreener cites −0.56x FY2026 | Peers: Biofrontera loss-making; Photocure near breakeven |
EV/EBITDA | n/m (negative EBITDA) | — |
EV/Sales (FY2026) | ~13x (computed); MarketScreener 12.4x | — |
P/B | ~0.78x (computed on A$5.32M equity); negative price/tangible book | — |
Capital Instruments
| Instrument | Face / carrying | Rate | Maturity / repayment | Notes |
|---|---|---|---|---|
R&D tax-incentive financing | A$400,000 principal; A$425,956 incl. interest | 16% p.a. | On receipt of FY2025 RDTI refund (~A$539,520 claimed) | Short-dated |
Convertible notes (Mar/Jun 2026) | A$1,250,000 face; A$1,100,967 host + A$20,638 derivative | 0% coupon (unsecured) | 5 Mar 2029 | Conversion at 80% of 15-day VWAP (floor/cap terms per offer documents not fully retrieved); A$244,000 held indirectly by the Chair |
Securities on Issue
| Security | Number | Exercise price | Expiry |
|---|---|---|---|
Listed options (IVXO) | 65,894,631 | A$0.14 | 30 Jun 2027 |
Broker listed options | 1,564,508 | stated as A$0.004 in AR (likely typographical; same class as IVXO) | 30 Jun 2027 |
Placement options | 14,825,716 | A$0.28 | 12 May 2028 |
Director fee options | 4,928,643 (+ other nil-priced 454,036) | Nil | 2028–2029 |
Director incentive options | 3,177,324 | A$0.086 | 11 Jun 2029 |
Blue Ocean advisory options | 2,551,724 | A$0.14 / A$0.488 | 2028 |
Other unlisted options | ~2,535,151 | A$0.12–A$1.70 | 2026–2028 |
Licence milestone shares (contingent) | 24,470,644 | Nil | On clinical milestones |
Analyst Conclusions
Management guidance
No quantitative guidance. Management's qualitative outlook (FY2026 AR) centres on reaching clinical and commercial milestones for Photosoft™, expanding partnerships with global healthcare companies, and securing commercial transactions. Consensus growth expectations: none (no coverage).
Bull case
-
Option value of a global platform at a micro-cap price: For ~A$5M EV, investors gain exposure to a perpetual global licence over >300 photosensitisers with patent life to ~2041, FDA ODD in anal cancer and early efficacy signals in prostate (40% response) and NMSC (p<.05 lesion reduction).
-
Capital-light, partner-funded pipeline: Hanlim (up to A$2M with Korean government backing), SANGMYUNG and Protect fund multiple programs while Invion keeps all IP — any one producing a co-development or licence deal could re-rate the stock materially relative to its A$4M market value.
-
Aligned insiders and improving structure: The Chair (~21.5% interest) personally backed the January 2026 notes, defers salary, and the Lind facility has been removed; adding a licensing-experienced independent director signals an imminent partnering push.
Bear case
-
Existential funding gap: A$0.59M cash against ~A$2.4M annual burn, negative working capital (−A$2.15M) and an auditor's going-concern flag imply near-term, highly dilutive raises at depressed prices (CN conversions already occurred at A$0.07 vs A$0.14 placements a year earlier).
-
Governance and related-party concentration: Combined Chair/CEO, one independent director, a licensor associated with the CEO's investment firm, and A$10.65M previously paid for licences later superseded — minority shareholders bear the cost of the RMWCG relationship.
-
Thin, early data in competitive markets: Open-label, small-n results face approved PDT systems (Ameluz, Levulan, Metvix) and anti-VEGF incumbents; Phase II/III costs are far beyond Invion's balance sheet, so value depends on a partner willing to pay.
Key catalysts and monitorables (next 12 months)
-
September 2026 quarter Appendix 4C (by 31 Oct 2026): cash, burn and any new funding.
-
AGM on 25 Nov 2026: capital-raising approvals (placement capacity, option issues).
-
Receipt of the FY2025 RDTI refund (~A$539,520) and repayment of the 16% R&D loan; lodgement/financing of the FY2026 claim.
-
NMSC trial: BCC cohort readouts and durability of complete responses.
-
Peter Mac anogenital trial: ethics approval and first patient dosed.
-
Hanlim/KDDF: completion of non-clinical package toward Australian IV INV043 first-in-human trial; potential trigger toward licence milestone 2 (IND-enabled Phase II start) over a longer horizon.
-
IP transfer from RMWCG to NGPDT IP (due within 12 months of the Dec 2025 deal).
-
SANGMYUNG wet AMD and Protect companion-animal PoC data; conversion into co-development agreements.
-
Progress of RDTI reform legislation.
-
Any sub-licensing transaction led by the refreshed board.
Concluding analyst verdict
Invion Limited is best understood as a heavily discounted call option on the Photosoft™ photosensitiser platform, held inside a balance sheet that cannot fund its own exercise. The December 2025 global licence materially improved the quality of the asset: it replaced a fragmented, cash-hungry web of territory licences with perpetual worldwide rights for selected human and animal indications, deferred most consideration into clinical-milestone shares, released the dysfunctional R&D services relationship with RMW Cho Group, and secured a founder guarantee pending IP transfer. Scientific signals are encouraging but immature — clean topical safety, statistically significant lesion reduction in NMSC, notable prostate responses in a licensor-run Phase II, and striking preclinical synergy with PD-1 inhibitors that earned FDA orphan status in anal cancer.
Against this, the financial position is precarious. With A$0.59 million of cash at 30 June 2026, roughly A$2.4 million of annual operating burn, negative working capital, an auditor's going-concern paragraph and a share price down about 97% over five years, Invion's immediate value driver is not science but financing. The next equity raise is likely to be priced near current levels and could materially dilute holders, compounded by a large options overhang and up to 24.5 million further licence shares. Governance — a combined Chair/CEO, a board with limited independence, and the CEO's investment firm being an associate of the licensor — warrants a discount and close scrutiny of any further related-party transactions.
The investment case therefore hinges on whether management can convert its partner-funded collaborations (Hanlim, SANGMYUNG, Protect) and the newly appointed licensing expertise into a cash-generating sub-licence before balance-sheet pressure forces punitive dilution. For risk-tolerant, specialist investors, the asymmetry is real; for most institutional mandates, Invion remains uninvestable until funding is secured and a third-party validation transaction is executed. Stance: Speculative / High Risk — monitor for a partnering transaction and recapitalisation terms.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Appointed / tenure | Prior roles | Education |
|---|---|---|---|---|
Prof. Thian Chew | Executive Chairman and CEO | Executive Chair & CEO since 31 Oct 2020; associated with Invion since 2017 | Managing Partner, Polar Ventures (since c.2013); co-founder, Chronic Airway Therapeutics; Executive Director, Goldman Sachs (New York, Hong Kong); Consultant Project Manager, Morgan Stanley; Director, KPMG Consulting (Singapore, Sydney); Senior Manager, KPMG (Taipei, Melbourne); Adjunct Associate Professor, HKUST; Visiting Professor, UCL Global Business School for Health; Advisory Board, Stanford Medicine CARE | MBA, Wharton (Palmer Scholar); MA, Lauder Institute (UPenn); B. Information Systems, Monash; Chartered Accountant |
Alan Yamashita | Non-Executive Director; Chair, Nomination & Remuneration Committee; Member, Audit & Risk Committee | — | Managing Partner, Polar Ventures; 16-year Goldman Sachs veteran; MD & Head of Asia Capital Markets, Merrill Lynch (1996–98); President & CEO, Search Investment Group (1999–2005) | MPA, BA |
Melanie Leydin | Non-Executive Director, Company Secretary and CFO | NED since 31 Aug 2024; Company Secretary since 28 Oct 2024 | Principal, Leydin Freyer (2000–2021, acquired by Vistra); EVP Global Solutions SE Asia, Vistra; director of Imagion Biosystems (ASX: IBX); former director of Unico Silver, Alchemia, Medibio | BBus (Acc. & Corp Law), FCA, FGIA |
Paul Field | Independent Non-Executive Director | Since 18 Aug 2026 | 30+ years in global biopharma business development, licensing and co-development; NED of 60 Degrees Pharmaceuticals (NASDAQ: SXTP) | BA (Hons), MA, FAICD |
Alistair Bennallack | Former NED; former Chair, Audit & Risk Committee | Resigned 18 Aug 2026 | COO/CFO, Village Roadshow Pty Ltd; CEO, Village Roadshow Theme Parks Asia | CA |
Rob Merriel | Former NED | Resigned 31 Aug 2024 | CFO, Chief Commercialisation Officer & Company Secretary, Hudson Institute | BA, Grad Dips, CPA |
Directors' Remuneration
| Name | Salary & fees | Cash bonus | Super | Long service leave | Equity-settled SBP | Total |
|---|---|---|---|---|---|---|
Thian Chew | 354,000 | 0 | 0 | 23,769 | 70,777 | 448,546 |
Alan Yamashita | 27,370 | 0 | 0 | 0 | 24,967 | 52,337 |
Alistair Bennallack | 27,370 | 0 | 0 | 0 | 24,967 | 52,337 |
Melanie Leydin | 60,000 | 0 | 0 | 0 | 0 | 60,000 |
Total | 468,740 | 0 | 0 | 23,769 | 120,711 | 613,220 |
Directors' Remuneration (Annual)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total KMP remuneration (AUD K) | 1,689 | 1,022 | 674 | 618 | 613 |
CEO total remuneration (AUD K) | 1,503 | 851 | 510 | 440 | 449 |
CEO cash bonus (AUD K) | 161 | 123 | 0 | 0 | 0 |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
31 Jul 2024 | Claire Newstead-Sinclair resigns as Company Secretary; Tai Phan appointed | Vistra team reassignment |
31 Aug 2024 | Rob Merriel resigns; Melanie Leydin appointed NED | Hudson-linked director departs |
28 Oct 2024 | Leydin appointed Company Secretary (replacing Phan) | Vistra reassignment |
Dec 2024 | Prof Robert Ramsay appointed Scientific Advisor | Anogenital program support |
Q4 FY2026 | Dr Colin Hopper appointed Clinical Advisor | Strengthen clinical governance, trial design |
18 Aug 2026 | Paul Field appointed Independent NED; Alistair Bennallack resigns | Adds BD/licensing expertise consistent with out-licensing strategy |
Major Shareholders
| Holder | Shares | % of 109.2M (computed) | Source / date |
|---|---|---|---|
Thian Chew — total relevant interest (direct 246,706; indirect 23,192,537, including Polar Ventures and the 12,235,322 RMWC Pty Ltd consideration shares deemed associated) | 23,439,243 | 21.5 | FY2026 Annual Report |
RMWC Pty Ltd (RMW Cho Group) — licence consideration shares (escrowed 12 months from 12 Jun 2026) — included in Chew's relevant interest | 12,235,322 | 11.2 | FY2026 Annual Report |
Polar Ventures Limited (older register) | 5,452,178 | 8.20 (as reported, ~66M share base) | Motley Fool AU (date not specified; likely late 2024) |
NGPDT Greater China Limited (older register) | 2,726,523 | 4.10 (as reported) | Motley Fool AU |
Citicorp Nominees Pty Limited (older register) | 2,468,145 | 3.00 (as reported; arithmetically ~3.7% on the same base — discrepancy) | Motley Fool AU |
Alistair Bennallack (former director) | 248,110 | 0.2 | FY2026 Annual Report |
Alan Yamashita | 150,053 | 0.1 | FY2026 Annual Report |
Competitive Landscape
Competitors by Segment
| Program | Competitor | Product / approach | Positioning vs Invion |
|---|---|---|---|
NMSC / dermatology PDT | Biofrontera Inc. (NASDAQ: BFRI) | Ameluz® (aminolevulinic acid gel) + RhodoLED® lamp; sNDA for superficial BCC accepted by FDA | Commercial-stage, US$41.7M revenue (FY2025); entrenched in dermatology PDT |
NMSC / dermatology PDT | Sun Pharmaceutical | Levulan® Kerastick® + BLU-U® (ALA) | Large-cap incumbent in AK PDT |
NMSC / dermatology PDT | Galderma | Metvix® / methyl aminolevulinate PDT (ex-US) | Global dermatology leader |
Advanced cSCC / BCC systemic | Regeneron / Sanofi | Libtayo® (cemiplimab) | Standard of care in advanced disease |
Advanced BCC | Roche (Erivedge®); Sun Pharma (Odomzo®) | Hedgehog inhibitors | Systemic alternatives |
Bladder cancer PDD/PDT | Photocure ASA (OSE: PHO) | Hexvix®/Cysview® blue-light cystoscopy | Commercial PDD peer; NOK 532.6M revenue (FY2025) |
Oncology PDT (NMIBC) | Theralase Technologies (TSXV: TLT) | Ruvidar™ (TLD-1433) PDT | — |
Vascular-targeted PDT | Steba Biotech (private) | TOOKAD® (padeliporfin) for prostate cancer | Approved in some markets (EU) |
Oncology PDT | Pinnacle Biologics | Photofrin® (porfimer sodium) — oesophageal and lung cancer | Legacy PDT incumbent in oesophageal indication |
Photoimmunotherapy | Rakuten Medical (private) | Akalux® (cetuximab sarotalocan), head & neck | Next-gen light-activated oncology |
Oesophageal systemic | BMS (Opdivo®), Merck (Keytruda®) | PD-1 inhibitors | Standard of care; Invion positions PDT as complementary |
Wet AMD | Regeneron (Eylea®), Roche (Vabysmo®), Novartis/Bausch (Visudyne® verteporfin PDT) | Anti-VEGF; legacy PDT | Dominant incumbents |
Companion-animal oncology | Zoetis, Elanco, Boehringer Ingelheim Animal Health | Veterinary oncology products | Large incumbents |
Peer Comparison FY2026
| Metric | Invion (FY2026, Jun) | Biofrontera Inc. (FY2025, Dec) | Photocure ASA (FY2025, Dec) |
|---|---|---|---|
Revenue | A$0.38M | US$41.7M | NOK 532.6M |
Revenue growth | n/m (from nil) | +12% | Hexvix/Cysview product revenue ~+10% (9% incl. FX) |
Gross margin | n/m | 73.7% | — |
Net result | Loss A$5.63M | Loss US$10.5M | Approx. loss NOK 1.5M (aggregator) |
Adjusted EBITDA | −A$3.94M (computed) | −US$10.6M | Commercial EBITDA NOK 55.9M |
R&D intensity | 385% of revenue | — | — |
Stage | Phase I/II | Commercial | Commercial |



